Market revenue in 2023 | USD 92.3 million |
Market revenue in 2030 | USD 210.9 million |
Growth rate | 12.5% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.86% in 2023. Horizon Databook has segmented the Saudi Arabia immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
The demand for immunoassays in the neurological biomarkers market in Saudi Arabia is likely to grow at a significant rate over the forecast period. High unmet clinical needs, a rise in disposable income, and an increase in the number of collaborative agreements with international organizations, such as WHO & UN, are creating demand for immunoassay tests for the identification of neurological biomarkers in Saudi Arabia.
Some of the key players operating in the country are F. Hoffmann La-Roche Ltd.; Bio-Rad Laboratories; and Merck. These companies provide various immunoassay tests and instruments for the diagnosis and research of neurodegenerative patients.
Saudi Food and Drug Authority (SFDA) regulates medical devices (including IVD) and is focused on devices used on humans. IVD developers have access to the Kingdom of Saudi Arabia market only if they are authorized by one of the founding members of the Global Harmonization Task Force (GHTF).
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account